"Although urinary11-dehydro-TXB2 levels are largely suppressed with low-dose aspirin, incomplete suppression by aspirin predicts the future risk of vascular events and death in high-risk patients and may identify individuals who might benefit from treatments that more effectively block in vivo TX production or activity. Several disease-modifying agents, including lifestyle intervention, antidiabetic drugs and antiplatelet agents besides aspirin have been shown to reduce TX biosynthesis."Read More
The thromboxane A2 pathway and its components are implicated in the progression of atherosclerosis and cardiovascular diseases. (CAD) Thromboxane A2 is clearly involved in CAD due to its acute and chronic role in promotion of vasoconstriction and platelet aggregation. The success of low-dose aspirin in prevention of CAD is explained by platelet COX-1 inhibiting thromboxane A2 biosynthesis. Levels of urinary 11-dehydrothromboxane B2 reflect activity of components of the thromboxane A2 pathway that regulate thromboxane A2 generation.
"Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease."
"Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality worldwide despite recent advances in its management and treatment. Inflammation is a key driver of the pathogenesis and progression of ASCVD in preclinical models and humans."Read More
"As a marker of in vivo thromboxane generation, high-level urinary thromboxane metabolites (TXA-M) increase the occurance of cardiovascular events in high-risk patients. To investigate whether perioperative urinary TXA-M level is associated with major adverse cardiac and cerebrovascular events (MACCE) after coronary artery bypass graft (CABG) surgery, we designed a nested case-control study."
"Post-CABG 24 hours urinary TXA-M elevation is associated with an increase of 1 year adverse events after CABG."Read More
"There is a variable cardiovascular risk reduction attributable to aspirin because of individual differences in the suppression of thromboxane A2 and its downstream metabolite 11-dehydrothromboxane B2 (11dhTxB2). Our data indicates the optimal cut point for urine 11dhTxB2 is 1597.8 (pg/mg) for the risk prediction of mortality over five years in stable patients with CAD patients treated with aspirin."Read More
"Long-term nonplatelet thromboxane generation after coronary artery bypass graft surgery is a novel risk factor for 5-year adverse outcome, including death. In contrast, nonplatelet thromboxane generation in the early postoperative period appears to be dirven predominantly by inflammation and did not independently predict long-term clinical outcome."Read More
"Soluble proprotein convertase subtilisin/kexin type 9 (PCSK9) has been shown to be predictive of cardiovascular events (CVEs) in patients who are at high cardiovascular risk. No data on the effect of PCSK9 levels in patients with atrial fibrillation (AF) are available. This study investigated the association between PCSK9 and CVEs in AF; as well as, the relationship between PCSK9 and urinary 11-dehydro-thromboxane B2 (11-dh-TxB2), a marker of platelet activation. Plasma PCSK9 levels are associated with an increased risk of CVEs in patients with AF. The direct correlation between PCSK9 and 11-dh-TxB2 suggests PCSK9 as a mechanism potentially implicated in platelet activation."Read More
"Urinary concentration of 11DHTXB2 was a strong independent risk factor for all-cause mortality among patients with stable CAD on aspirin therapy and may be a marker for patients with CAD who require more intensive secondary prevention measures."Read More
"Urinary 11-dehydro-thromboxane (TX)B2 has been described as a potential predictive biomarker of major adverse cardiovascular events (MACEs) in high cardiac risk patients.”
“11-Dehydro-TXB2 predicts 1-year cumulative MACEs in AMI patients and provides prognostic information on the left ventricular performance."Read More
"Urinary 11-dehydrothromboxane B2 (UTBx) was associated with an increased risk of thrombotic events in two major clinical trials of cardiovascular disease. The utility of UTBx as a thrombotic risk marker in patients treated with a left ventricular assist device (LVAD) is unknown. In this first report the serial assessment of UTBx and measurement of UTBx at the time of adverse event occurrence in LVAD recipients, UTBx was associated with aspirin dose, bleeding and thrombotic events."Read More
"Statin and aspirin form the therapeutic cornerstone in patients with coronary artery disease and diabetes. Little is known about relationship of statins with blood thrombogenicity and inflammation in these patients."
"Statins along with aspirin, confers additional anti-inflammatory and antithrombotic effect in diabetics with CAD. Urinary 11-DHTXB2 may be a useful biomarker for personalizing statin therapy."Read More